

VRL/SEC/BSE

03.08.2013

Dept. of Corporate Services  
The Stock Exchange, Mumbai  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai

Sub.: Unaudited Financial Results (Provisional) for the quarter ended on  
30.06.2013

Dear Sir/Madam,

This is to inform you that there was a typing error in previous Unaudited Financial Results (Provisional) for the quarter ended on 30.06.2013 we emailed to BSE.


The column of quarter result as on 31.03.2013 is audited not unaudited.

Kindly publish the revised results on your website.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,  
for VENUS REMEDIES LIMITED

  
Neha Kodari  
(Company Secretary)



## NUS REMEDIES LIMITED

Corporate Office :

Industrial Area, Phase- I,  
Panchkula (Hry.) 134113, India

Office :

57, Cabin No. 10, 2nd Floor, NAC,  
Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[venusmedicineresearchcentre.com](http://venusmedicineresearchcentre.com)



Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India

Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)**  
**FOR THE QUARTER ENDED 30TH JUNE, 2013**

Rs in MILLION  
Year Ended on

No.	PARTICULARS	Quarter Ended on			
		30/06/2013 Unaudited	31/03/2013 Audited	30/06/2012 Unaudited	31/03/2013 Audited
	<b>Part - I</b>				
	<b>Net Sales/ Income from operations</b>				
	Gross Sales	1268.79	1253.11	1123.75	4,602.58
	Less : Excise Duty	2.34	2.83	3.41	11.61
	(a) Net Sales	1266.45	1250.28	1120.34	4,590.97
	(b) Other Operating Income	5.63	2.89	5.38	22.41
	<b>Total Income from Operation ( Net )</b>	<b>1,272.08</b>	<b>1,253.17</b>	<b>1,125.72</b>	<b>4,613.38</b>
	<b>Expenses</b>				
	(a) Consumption of raw materials	752.50	785.68	652.37	2,725.58
	(b) (Increase)/ Decrease in stock in trade	-2.80	-31.83	-29.75	92.93
	(c) Employee benefits expense	59.17	58.87	57.10	232.38
	(d) Depreciation & amortization expense	95.35	80.07	77.69	317.62
	(e) Other expenses	147.14	139.68	148.80	563.47
	<b>Total expense</b>	<b>1,051.36</b>	<b>1,032.47</b>	<b>906.21</b>	<b>3,746.12</b>
	<b>Profit from operations before other income , finance costs and exceptional items ( 1-2)</b>	<b>220.72</b>	<b>220.70</b>	<b>219.51</b>	<b>867.26</b>
	Other income	8.18	-3.45	1.26	3.95
	<b>Profit before finance costs and exceptional items (3+4)</b>	<b>228.90</b>	<b>217.25</b>	<b>220.77</b>	<b>871.21</b>
	Finance Costs	66.81	61.68	76.15	244.49
	<b>Profit after finance costs but before exceptional items (5-6)</b>	<b>162.09</b>	<b>155.57</b>	<b>144.62</b>	<b>626.72</b>
	Exceptional Items	0.00	0	0.00	00.00
	<b>Profit from ordinary activities before tax (7+8)</b>	<b>162.09</b>	<b>155.57</b>	<b>144.62</b>	<b>626.72</b>
	Tax expense	8.97	36.04	4.17	55.27
	<b>Profit from ordinary activities after tax (9+10)</b>	<b>153.12</b>	<b>119.53</b>	<b>140.45</b>	<b>571.45</b>
	Exceptional items ( net of tax expense	00.00	0.00	00.00	0.00
	<b>Net profit for the period ( 11-12)</b>	<b>153.12</b>	<b>119.53</b>	<b>140.45</b>	<b>571.45</b>
	<b>Raid up Equity Share Capital</b>	<b>114.42</b>	<b>105.42</b>	<b>97.42</b>	<b>105.42</b>
	<b>Reserves excluding revaluation reserves</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>3,769.22</b>
	<b>E.P.S - Basic not annualised for the qtr</b>	<b>13.38</b>	<b>11.34</b>	<b>14.42</b>	<b>54.21</b>
	- Annualised	53.53	45.35	57.67	54.21
	<b>Part - II (A)</b>				
	<b>Public Shareholding</b>				
	a- Number of Shares	6437086	6437086	6388986	6437086
	b- Percentage of Shareholding	56.26	61.06	65.58	61.06
	<b>Promoters and promoter group shareholding</b>				
	a) Pledged as collateral security to bank				
	- Number of Shares	1930000	1930000	1930000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	38.56	47.02	57.56	47.02
	- Percentage of shares (as a % of the total share capital	16.87	18.31	19.81	18.31
	b) Non-Encumbered				
	- Number of Shares	3074902	2174902	1423002	2174902
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	61.44	52.98	42.44	52.98
	- Percentage of shares (as a % of the total share capital	26.87	20.63	14.61	20.63
	<b>Particulars</b>	<b>3 months ended 30.06.13</b>			
	<b>INVESTOR COMPLAINTS</b>				
	existing at the beginning of the quarter				NIL
	received during the quarter				1
	disposed of during the quarter				1
	remaining unresolved at the end of the quarter				NIL





**Notes:**

1. The above Un-audited (Provisional) financial Results for the period ended 30.06.2013 were reviewed by the Audit Committee and taken on record at the board Meeting on August 3, 2013.
2. During the Quarter:
  - a) The Company has made it to the list of Top 100 in the "India's Best Companies to Work for" study conducted by the Great Place to Work Institute, India in association with The Economic Times Placed at the 72<sup>nd</sup> position.
  - b) The Company has received Mexico patent for its research product 'POTENTOX'.
  - c) The Company has been awarded Gold Medal by DST\_Lockheed Martin India Innovation growth program - 2013 for its research product 'ELORES'.
  - d) The Company out -licensed Elores a novel antibiotic adjuvant entity for South Korea after patent grant.
3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.
4. During the Quarter, one investor grievance was received and resolved. No other investor grievance was pending at the end of the quarter.
5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors  
For VENUS REMEDIES LIMITED

  
(Pawan Chaudhary)

Chairman & Managing Director

Place : Panchkula  
Date : 03.08.13